Orforglipron

Grade A: Approved and proven

TL;DR: Orforglipron (brand name Foundayo) is a non-peptide oral small-molecule GLP-1 receptor agonist developed by Eli Lilly, approved by FDA on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity. As the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions, it addresses a key limitation of peptide-based GLP-1 agents and oral semaglutide, which require fasting administration. Phase 3 ATTAIN program data (multiple trials across obesity and type 2 diabetes populations) demonstrated clinically meaningful weight reduction, with GI adverse event rates consistent with the GLP-1 class. The compound received the fastest NME approval since 2002, approved 50 days after filing. Evidence is Grade A, reflecting FDA approval based on adequate and well-controlled trials.

Key Takeaways

Grade A: Approved and proven
FDA approved: FDA-approved April 1, 2026, for obesity (BMI at least 30 kg/m²) or overweight (BMI at least 27 kg/m²) with at least one weight-related comorbidity.
Compounding: FDA-approved branded product (Foundayo); compounding is not appropriate. As a small-molecule drug, it is not a biologic and not on peptide compounding lists. Dispensing requires a valid prescription; no compounding pathway exists for this approved chemical entity.

Orforglipron chemical structure — Structure via PubChem CID 137319706

Mechanism

Non-peptide small molecule that selectively activates the GLP-1 receptor, suppressing appetite through central and peripheral pathways, slowing gastric emptying, and enhancing glucose-dependent insulin secretion.

Evidence

Orforglipron (brand name Foundayo) is a non-peptide oral small-molecule GLP-1 receptor agonist developed by Eli Lilly, approved by FDA on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity. As the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions, it addresses a key limitation of peptide-based GLP-1 agents and oral semaglutide, which require fasting administration. Phase 3 ATTAIN program data (multiple trials across obesity and type 2 diabetes populations) demonstrated clinically meaningful weight reduction, with GI adverse event rates consistent with the GLP-1 class. The compound received the fastest NME approval since 2002, approved 50 days after filing. Evidence is Grade A, reflecting FDA approval based on adequate and well-controlled trials.

Safety and risks

Foundayo carries an FDA boxed warning for thyroid C-cell tumors: GLP-1 receptor agonists pharmacologically active in rodents have caused thyroid C-cell adenomas and carcinomas. Notably, orforglipron itself showed no pharmacological activity in rats or mice and produced no thyroid tumors in rodent studies; however, because human relevance cannot be fully excluded, the precautionary boxed warning is retained. Foundayo is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Serious warnings and precautions in the approved label include: acute pancreatitis (discontinue if suspected); severe gastrointestinal reactions (not recommended in severe gastroparesis; 3% serious GI reactions vs. 1% placebo); acute kidney injury from volume depletion due to GI fluid losses; hypoglycemia when combined with insulin or insulin secretagogues (dose reduction of the secretagogue should be considered); serious hypersensitivity reactions including anaphylaxis and angioedema; diabetic retinopathy complications (monitor for progression in T2D patients); acute gallbladder disease; and pulmonary aspiration risk during general anesthesia or deep sedation from delayed gastric emptying. Common adverse reactions (at least 5% incidence in pivotal trials) include nausea (up to 35% at 17.2 mg vs. 10% placebo), constipation (up to 27% vs. 9%), diarrhea (up to 25% vs. 11%), vomiting (up to 24% vs. 4%), dyspepsia, abdominal pain, and headache; 8% of participants discontinued due to adverse reactions versus 3% on placebo, primarily GI-related. Hair loss was also reported.

Interactions

Significant interactions documented in approved label: strong CYP3A4 inhibitors that also inhibit OATP1B require dose capping at 9 mg; strong CYP3A4 inducers should be avoided; moderate inducers require monitoring and potential dose escalation. Simvastatin dose must not exceed 20 mg daily (orforglipron causes approximately 2-fold increase in simvastatin active metabolite exposure). Concomitant insulin or insulin secretagogues increase hypoglycemia risk (consider secretagogue dose reduction). Oral contraceptives: delayed gastric emptying may reduce absorption; switch to non-oral method or add barrier contraception for 30 days after initiation and each dose escalation. Do not use concomitantly with another GLP-1 receptor agonist.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

FDA-approved branded product (Foundayo); compounding is not appropriate. As a small-molecule drug, it is not a biologic and not on peptide compounding lists. Dispensing requires a valid prescription; no compounding pathway exists for this approved chemical entity.

Sources

Orforglipron is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).